

Philochem, InterX and Scripps Research announce a Research Collaboration in the Field of DNA-Encoded Chemistry and Tumor Targeting

Siena, Italy, Menlo Park and La Jolla, California, August 23rd, 2021

Philochem, a wholly owned subsidiary of Philogen S.p.A., a publicly-listed company, InterX, Inc., a privately-owned company, and Scripps Research, a non-profit American medical research facility, today announced the signature of a research collaboration to discover new small molecule therapeutics using Philochem's and Scripps' proprietary DNA-Encoded Chemical Library (DEL) technology and InterX's proprietary computational chemical biology software platform.

This collaboration brings together Nobel laureates Roger Kornberg and Michael Levitt with leading DEL technology scientists Richard Lerner and Dario Neri. The team will collaborate on the development of a best-in-class targeting agent for metastatic prostate cancer, a disease that affects millions of patients worldwide.

Prof. Richard Lerner is Institute Professor at Scripps Research, one of the world's leading Institutions in chemical and biomedical research. He first postulated the principle of DEL technology in 1992.

Philochem is a fully-owned subsidiary of the Philogen group, focused on the development of therapeutic products isolated from DNA-encoded chemical libraries. Philogen is a Swiss-Italian clinical-stage company, listed on the Italian stock exchange (Borsa Italiana). Philochem and Philogen were co-founded by Prof. Dario Neri (the Chief Executive Officer of the company), a pioneer in DEL research and a professor at ETH Zürich. For more information please visit www.philogen.com and www.philochem.com.

InterX is a biotechnology start-up company, based in the United States and Israel, which is revolutionizing biomolecular computation of chemical and biological systems. The company aims to achieve robust and accurate prediction of molecular and ensemble properties of biological systems using computational methods. InterX is led by Nobel Prize-winning scientist Roger Kornberg. For more information please visit www.interx.dev.

Philogen contacts

Dr. Christian Lizak (Business Development), Dr. Emanuele Puca (Investor Relations)

+41 (0) 43 544 88 00

christian.lizak@philogen.com, emanuele.puca@philogen.com

Consilium Strategic Communications contacts

Mary-Jane Elliott, Davide Salvi

philogen@consilium-comms.com